Search research articles
Contact Us
Filters
Showing results (21-30 of 48) with videos related to
Page
of 5
Sort By:
Journal of Molecular Medicine (Berlin, Germany)
|
September 25, 2007
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
Nathalie Chaput, Stéphane De Botton, Michel Obeid, et al.
EMBO Molecular Medicine
|
December 21, 2012
Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria
Michel Obeid, Jean-François Franetich, Audrey Lorthiois, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 21, 2020
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis
Laura Moi, Hasna Bouchaab, Nuria Mederos, et al.
Journal of Neurology
|
December 23, 2023
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series
Alex Vicino, Andreas F Hottinger, Sofiya Latifyan, et al.
Revue Medicale Suisse
|
June 5, 2020
[Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Dimitri Arangalage, Anna Giulia Pavon, Sarah Hugelshofer, et al.
The Lancet. Oncology
|
January 8, 2019
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins, Gerasimos P Sykiotis, Michel Maillard, et al.
Journal for Immunotherapy of Cancer
|
October 25, 2022
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Alexander Coukos, Julien Vionnet, Michel Obeid, et al.
Nature Communications
|
May 1, 2024
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Victor Joo, Karim Abdelhamid, Alessandra Noto, et al.
Immunological Reviews
|
November 6, 2007
Ecto-calreticulin in immunogenic chemotherapy
Michel Obeid, Antoine Tesniere, Theocharis Panaretakis, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 48) with videos related to
Sort By:
Page
of 5
Journal of Molecular Medicine (Berlin, Germany)
|
September 25, 2007
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
Nathalie Chaput, Stéphane De Botton, Michel Obeid, et al.
EMBO Molecular Medicine
|
December 21, 2012
Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria
Michel Obeid, Jean-François Franetich, Audrey Lorthiois, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 21, 2020
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis
Laura Moi, Hasna Bouchaab, Nuria Mederos, et al.
Journal of Neurology
|
December 23, 2023
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series
Alex Vicino, Andreas F Hottinger, Sofiya Latifyan, et al.
Revue Medicale Suisse
|
June 5, 2020
[Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Dimitri Arangalage, Anna Giulia Pavon, Sarah Hugelshofer, et al.
The Lancet. Oncology
|
January 8, 2019
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins, Gerasimos P Sykiotis, Michel Maillard, et al.
Journal for Immunotherapy of Cancer
|
October 25, 2022
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Alexander Coukos, Julien Vionnet, Michel Obeid, et al.
Nature Communications
|
May 1, 2024
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Victor Joo, Karim Abdelhamid, Alessandra Noto, et al.
Immunological Reviews
|
November 6, 2007
Ecto-calreticulin in immunogenic chemotherapy
Michel Obeid, Antoine Tesniere, Theocharis Panaretakis, et al.
Page
of 5